{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:24:25Z","timestamp":1782476665573,"version":"3.54.5"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Adrenocortical carcinoma (ACC) is a rare but aggressive endocrine malignancy that usually results in a fatal outcome. To allow the better clinical management and reduce mortality, we searched for clinical and molecular markers that are reliable predictor of disease severity and clinical outcome in ACC patients. We determined a correlation between the overexpression of<jats:italic>IL-13R<\/jats:italic>\u03b12 and the clinical outcome in ACC patients using comprehensive data available in The Cancer Genome Atlas (TCGA) database. The dataset of 79 ACC subjects were divided into groups of low, medium, or high expression of<jats:italic>IL-13R<\/jats:italic>\u03b12 as determined by RNA-seq. These patients were also stratified by length of survival, overall survival, incidence of a new tumor event, incidence of metastasis, and production of excess hormones. We report a correlation between<jats:italic>IL-13R<\/jats:italic>\u03b12 expression and survival of subjects with ACC. High expression of<jats:italic>IL-13R\u03b1<\/jats:italic>2 in ACC tumors was significantly associated with a lower patient survival rate and period of survival compared to low expression (p = 0.0084). In addition, high<jats:italic>IL-13R<\/jats:italic>\u03b12 expression was significantly associated with a higher incidence of new tumor events and excess hormone production compared to low or medium<jats:italic>IL-13R<\/jats:italic>\u03b12 expression. Within the cohort of patients that produced excess hormone, elevated<jats:italic>IL-13R<\/jats:italic>\u03b12 expression was significantly associated with a lower survival rate. Additionally,<jats:italic>IL-13R<\/jats:italic>\u03b11 had a potential relationship between transcript level and ACC survival. Our results and promising antitumor activity in preclinical models and trials indicate that<jats:italic>IL-13R<\/jats:italic>\u03b12 expression is an important prognostic biomarker of ACC disease outcome and a promising target for therapeutic treatment of ACC.<\/jats:p>","DOI":"10.1371\/journal.pone.0246632","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T21:33:33Z","timestamp":1613511213000},"page":"e0246632","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["IL-13R\u03b12 gene expression is a biomarker of adverse outcome in patients with adrenocortical carcinoma"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-0215","authenticated-orcid":true,"given":"Abhinav","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"Bellayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hridaya S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2548-346X","authenticated-orcid":true,"given":"Raj K.","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"issue":"2","key":"pone.0246632.ref001","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.beem.2008.10.008","article-title":"Clinical management of adrenocortical carcinoma","volume":"23","author":"M Fassnacht","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"pone.0246632.ref002","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"T Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"2","key":"pone.0246632.ref003","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4049\/jimmunol.158.2.756","article-title":"The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor","volume":"158","author":"NI Obiri","year":"1997","journal-title":"J Immunol"},{"issue":"3","key":"pone.0246632.ref004","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11060-017-2680-9","article-title":"Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor alpha1 and alpha2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme","volume":"136","author":"J Han","year":"2018","journal-title":"J Neurooncol"},{"issue":"2","key":"pone.0246632.ref005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ijc.26366","article-title":"IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK\/AP-1 pathway in mouse model of human ovarian cancer","volume":"131","author":"T Fujisawa","year":"2012","journal-title":"Int J Cancer"},{"issue":"11","key":"pone.0246632.ref006","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/0008-5472.CAN-11-4090","article-title":"High expression of IL-13 receptor alpha2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis","volume":"72","author":"R Barderas","year":"2012","journal-title":"Cancer Res"},{"issue":"2","key":"pone.0246632.ref007","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1078-0432.CCR-09-2015","article-title":"Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy","volume":"16","author":"T Shimamura","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"22","key":"pone.0246632.ref008","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1002\/cncr.27629","article-title":"Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma","volume":"118","author":"M Jain","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"pone.0246632.ref009","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archsurg.143.9.841","article-title":"Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling","volume":"143","author":"GG Fernandez-Ranvier","year":"2008","journal-title":"Arch Surg"},{"issue":"2","key":"pone.0246632.ref010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cell.2008.01.006","article-title":"A new look at cytokine signaling","volume":"132","author":"A Zdanov","year":"2008","journal-title":"Cell"},{"issue":"51","key":"pone.0246632.ref011","doi-asserted-by":"crossref","first-page":"pe55","DOI":"10.1126\/scisignal.1.51.pe55","article-title":"Untangling the complex web of IL-4- and IL-13-mediated signaling pathways","volume":"1","author":"M Wills-Karp","year":"2008","journal-title":"Sci Signal"},{"issue":"1","key":"pone.0246632.ref012","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cyto.2015.05.026","article-title":"Targeting of IL-4 and IL-13 receptors for cancer therapy","volume":"75","author":"A Suzuki","year":"2015","journal-title":"Cytokine"},{"issue":"1","key":"pone.0246632.ref013","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nm1332","article-title":"IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis","volume":"12","author":"S Fichtner-Feigl","year":"2006","journal-title":"Nat Med"},{"issue":"26","key":"pone.0246632.ref014","doi-asserted-by":"crossref","first-page":"24915","DOI":"10.1074\/jbc.M502571200","article-title":"Characterization of the interaction between interleukin-13 and interleukin-13 receptors","volume":"280","author":"K Arima","year":"2005","journal-title":"J Biol Chem"},{"issue":"10","key":"pone.0246632.ref015","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/neuonc\/nou045","article-title":"Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy","volume":"16","author":"B Thaci","year":"2014","journal-title":"Neuro Oncol"},{"issue":"7","key":"pone.0246632.ref016","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1535-7163.MCT-10-1064","article-title":"Silencing IL-13Ralpha2 promotes glioblastoma cell death via endogenous signaling","volume":"10","author":"LC Hsi","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"pone.0246632.ref017","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2217\/imt.09.8","article-title":"IL-13 receptor-alpha2: a novel target for cancer therapy","volume":"1","author":"BH Joshi","year":"2009","journal-title":"Immunotherapy"},{"issue":"7","key":"pone.0246632.ref018","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/cam4.449","article-title":"Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma","volume":"4","author":"Y Liu-Chittenden","year":"2015","journal-title":"Cancer Med"},{"issue":"7","key":"pone.0246632.ref019","doi-asserted-by":"crossref","first-page":"e69958","DOI":"10.1371\/journal.pone.0069958","article-title":"Comparing the quality of crowdsourced data contributed by expert and non-experts","volume":"8","author":"L See","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"pone.0246632.ref020","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/cncr.22134","article-title":"Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy","volume":"107","author":"M Kioi","year":"2006","journal-title":"Cancer"},{"key":"pone.0246632.ref021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1758-3284-1-27","article-title":"Identification of potential therapeutic targets in human head & neck squamous cell carcinoma","volume":"1","author":"J Han","year":"2009","journal-title":"Head Neck Oncol"},{"issue":"4","key":"pone.0246632.ref022","first-page":"1103","article-title":"IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells","volume":"62","author":"SO Rahaman","year":"2002","journal-title":"Cancer Res"},{"issue":"1","key":"pone.0246632.ref023","first-page":"1","article-title":"15-Lipoxygenase-1 induces lipid peroxidation and apoptosis, and improves survival in rat malignant glioma","volume":"26","author":"H Viita","year":"2012","journal-title":"In Vivo"},{"issue":"2","key":"pone.0246632.ref024","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejca.2014.11.010","article-title":"Recurrence and cancer-specific survival according to the expression of IL-4Ralpha and IL-13Ralpha1 in patients with oral cavity cancer","volume":"51","author":"M Kwon","year":"2015","journal-title":"Eur J Cancer"},{"issue":"12","key":"pone.0246632.ref025","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1245\/s10434-017-5907-2","article-title":"Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer","volume":"24","author":"MH Park","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"pone.0246632.ref026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-015-0047-3","article-title":"Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study","volume":"3","author":"AP Fay","year":"2015","journal-title":"J Immunother Cancer"},{"issue":"12","key":"pone.0246632.ref027","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1078-0432.CCR-11-2692","article-title":"Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer","volume":"18","author":"M Volante","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"8","key":"pone.0246632.ref028","doi-asserted-by":"crossref","first-page":"e105855","DOI":"10.1371\/journal.pone.0105855","article-title":"CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma","volume":"9","author":"CL Ronchi","year":"2014","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T08:43:13Z","timestamp":1724488993000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246632"}},"subtitle":[],"editor":[{"given":"Pankaj K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0246632","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]}}}